EP1682186A2 - Hyperverzweigte polymer-konjugate über nichtenzymatische spaltbare verbindungsglieder - Google Patents

Hyperverzweigte polymer-konjugate über nichtenzymatische spaltbare verbindungsglieder

Info

Publication number
EP1682186A2
EP1682186A2 EP04765740A EP04765740A EP1682186A2 EP 1682186 A2 EP1682186 A2 EP 1682186A2 EP 04765740 A EP04765740 A EP 04765740A EP 04765740 A EP04765740 A EP 04765740A EP 1682186 A2 EP1682186 A2 EP 1682186A2
Authority
EP
European Patent Office
Prior art keywords
groups
composition
protein
mol
branching
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04765740A
Other languages
English (en)
French (fr)
Other versions
EP1682186B1 (de
Inventor
Dirk Vetter
Ulrich Hersel
Harald Rau
Robert Schnepf
Thomas Wegge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma GmbH
Original Assignee
Complex Biosystems GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Complex Biosystems GmbH filed Critical Complex Biosystems GmbH
Priority to EP04765740.8A priority Critical patent/EP1682186B1/de
Priority to EP16160207.3A priority patent/EP3085388B1/de
Priority to DK09161150.9T priority patent/DK2090323T3/en
Priority to EP09161150.9A priority patent/EP2090323B1/de
Publication of EP1682186A2 publication Critical patent/EP1682186A2/de
Application granted granted Critical
Publication of EP1682186B1 publication Critical patent/EP1682186B1/de
Priority to CY20141100190T priority patent/CY1114972T1/el
Priority to CY20161101093T priority patent/CY1119457T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
    • Y10S977/705—Protein or peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/754—Dendrimer, i.e. serially branching or "tree-like" structure

Definitions

  • the present invention relates to inclusion compounds comprising a protein and an encapsulating organic compound (EOC), which will also be referred to as proteophore, in a 1:1 stoichiometrie.
  • EOC encapsulating organic compound
  • the EOC is a dendrimer, resulting in a dendrimer- protein inclusion compound (DPIC).
  • DPIC dendrimer- protein inclusion compound
  • the EOC is a macrocyclic structure resulting in a macrocycle-protein inclusion compound (MPIC).
  • the encapsulating compounds, as well as the resulting inclusion compounds are water soluble and lend themselves for the controlled release of the protein to a target, preferably in a living body, in particular a mammal.
  • Proteins are large and unstable molecules. A large amount of proteins is known which show an important pharmacological activity. Examples include insulin, interferon, growth hormones and blood forming factors. In general, proteins are applied to mammals and humans by injection. To date, it is not possible to apply pharmacologically active proteins orally or transdermally. Following the injection, the proteins are readily attacked and often partially or totally eliminated by the immune system, various enzymes or kidney filtration. In addition, the protein can be toxic or cause allergic reactions.
  • Supramolecular chemistry is directed towards the synthesis and analysis of inclusion compounds in which two or more components are associated through complete enclosure of one set of molecules in a suitable structure formed by another.
  • one molecular entity is complementary to a different, second entity.
  • Complementarity can occur in shape or physicochemical properties or in a combination of both.
  • shape complementarity the host molecule forms a cavity of size similar to the guest molecule.
  • the host is termed cavitand, and the host-guest aggregate cavitate.
  • the stoichiometry of the supramolecular system is 1:1. Nevertheless, various types of complex stoichiometries are known. Guest molecules are typically smaller in size than the corresponding host compound.
  • Examples for small host-guest systems are for instance complexes formed between crown ethers and sodium or potassium ions.
  • Well-known examples for synthetic organic host-guest molecules are the complexation of aromatic compounds such as nitrophenol by cyclodextrin carbohydrates. Cyclodextrins come in various ring sizes, the larger of which can accomodate bicyclic structures such 1 as naphthalene and derivatives. Fullerene molecules are of spherical shape and accomodate free space of a diameter of 0.7 nm.
  • Biomacromolecules such as starch can form inclusion complexes with small guests such as iodine by filling a channel-like volume in the interior of a helix.
  • DNA double helices are known to accomodate rigid aromatic compounds by means of intercalation.
  • Serum albumin is a well-studied example of a protein that can be loaded with several molecules of fatty acids.
  • a large number of molecular medicines are based on proteins or peptides of which group insulin, interferons, growth hormones and blood factors are among the most widely used therapeutics.
  • Protein therapeutics are known to suffer from various drawbacks. Proteins are inherently instable macromolecules as their bioactivity depends upon the correct three-dimensional positioning of its polypeptide chain. External factors such as solvents, surfaces, agitation, temperature or pH may effect the conformational equilibrium and result in partial or total unfolding, denaturation, agglomeration or precipitation. Proteins of non-human origin or proteins containing non-human amino acid sequences are highly immunogenic. Antibody formation is even notable for human proteins such as insulin if frequently administered by injection. Biomolecules may be cleared from circulation too fast or too slow for a given therapeutic application and may exhibit a narrow therapeutic window. Proteins can be degraded by endogenous proteases.
  • proteins need to be efficiently encapsulated for protection and released from the encapsulating agent for bioactivity.
  • Proteins are composed of condensated amino acid sequences that fold into a compact three- dimensional arrangement, often of globular shape.
  • the diameter for globular proteins typicaly ranges from 1 to 10 nm.
  • Proteins can form complexes comprised of several identical or different subunits, and several proteins can associate to form even larger complexes.
  • a protein encapsulating agent has to provide a well-hydrated internal volume of a similar size and approximately spherical or ellipsoidal or channel-like shape.
  • the water content is an important molecular property, as most biomolecules depend on a hydration shell for bioactivity.
  • Linear or branched water soluble polymers can occupy a volume of similar size or greater than a protein molecule.
  • Polyethyleneglycol is a polymer of low toxicitiy and immunogenicity.
  • Various therapeutic proteins have been covalently conjugated to PEG by a process called PEGylation and successfully applied in molecular therapy (Harris JM, Chess RB, Nature (2003) 214-21).
  • An advantage of protein PEGylation is the improvement of pharmacokinetic properties of the conjugate in circulation.
  • PEG is widely used to render surfaces protein adsorption resistant and to precipitate proteins from aqueous solution, corroborating the notion that PEG does not physicochemically bind to protein.
  • the shielding effect may be enhanced by employing branched PEG.
  • Polyethylene glycol with a low degree of branching is known from US 5,643,575 and the 2003 catalogue of Nektar Therapeutics.
  • WO 01/21197 mentions branched monosubstituted insulin-PEG conjugates.
  • the steric shielding mechanism explains for the observed reduction of bioactivity of PEGylated proteins.
  • Covalent conjugation of protein side chains close to an epitope generally may impair the ability of the protein to bind to its receptor. Care has to be taken to identify a reactive protein side chain that is in a distal position to the region of the protein surface that is mediating receptor binding or enzymatic activity. For this reason, PEG monoconjugation is preferred over multiple conjugation. Nevertheless even for monoconjugates, various regioisomers are obtained in various ratios.
  • Steric shielding may also be enhanced by conjugating the protein to more than one PEG molecule. Multiple PEGylation leads to an apparent increase in hydrodynamic volume and serves better to protect the protein from antibody recognition or protease attack. The approach is compromised by loss of bioactivity, loss of therapeutic activity per gram of material and by increasing the risk of protein inactivation by conformational destabilization.
  • Non-water soluble polymers such as poly(lactide-co-glycolide, PLG) may form nano- or microparticles if precipitated from aqueous solution under certain conditions.
  • the formed particles are not water-soluble but are suspended in aqueous solution. Proteins present in the aqueous phase may be entrapped inside these non-covalent assemblies. Proteins are released as the particles degrade.
  • Such hydrogels are successfully used in slow release formulations of therapeutic proteins such as growth hormone (Tracy MA, Biotechnol Prod 14 (1998) 108-15).
  • Proteins or polypeptides may be incorporated in polymeric material by carrying out the polymerization step in the presence of the biomolecule. Insulin has been loaded to n- butylcyanoacrylate nanoparticles in this fashion (WO 96/31231). Polymerizing monomers are highly reactive molecular species and the process usually requires organic solvents. Biomacromolecules may suffer structural modification or degradation under such conditions.
  • Typical encapsulation methods involving prepolymerized entities are water-in-oil-in-water (w/o/w) double emulsion/solvent evaporation or the solid-in-oil-in-water (s/o/w) technique.
  • the encapsulation process involves organic solvents such as methylene chloride, heat and sonication or homogenization and therefore can lead to inactivation of the encapsulated material.
  • An alternative method is based on polymer crosslinking.
  • Proteins may be permanently entrapped in polymers if the crosslinking step is carried out in the presence of the protein. Protein, monomers and crosslinker are mixed and polymerized. Such polymers are not soluble per se.
  • Crosslinked polymers are constituted of a network of polymer chains. Within this network various pores and cavities and channels exist in a random fashion, some of which may be sufficiently large to allow for diffusion of protein into, through or out of the polymer. The degree of crosslinking has a strong effect on diffusion into and effusion from the polymer. Products from such crosslinking are called hydrogels, as they can be produced from water-soluble, well-hydrated components and exhibit considerable swelling behaviour.
  • the protein is put under stress as the protein is forced to make tight contact with the more hydrophobic polymer molecules. This again may cause additional denaturing and loss of activity. Additionally, the molecular architecture of the polymer network imposes mechanical and physicochemical stress on the protein.
  • the protein may be dehydrated or denatured by aggregation or contact to internal surfaces, and it is difficult to analyze the protein's bioactivity after encapsulation.
  • the release of proteins from the entrapment can be achieved by diffusion, a chemical or enzymatic reaction leading to degradation of the polymer or solvent activation (through osmosis or swelling) or a combination of mechanisms.
  • effusion, swelling or biodegradation mechanisms take place in vivo and are difficult to control.
  • Liposomes can form small unilamellar vesicles or large, multilamellar assemblies (Refs).
  • the encapsulation of drugs in liposomes has been studied extensively and is applied in molecular therapy.
  • WO 03/030829 describes liposome-encapsulated insulin formulations. Typical techniques such as mixing the drug with the lipid in an organic solvent, addition of an aqueous medium and subsequent removal of the organic solvent or dialysis of mixed lipid- detergent micelles are not readily applied to protein encapsulation due to protein denaruration by solvent or detergent.
  • a more suitable approach is lipid film hydration. Liposomes are formed by hydrating and dispensing a previously dried film of lipid.
  • Liposomes are not per se water-soluble but can be homogeneously distributed in water by means of dispersion. If protein is present in the hydration solution it becomes both associated on the surface and entrapped in the interior of the liposomes. The process reduces the exposure of protein to denaturing conditions but is of little encapsulation efficiency.
  • Dendrimers are well-defined polymeric structures. Dendrimers are based on repeating hyperbranched structures emanating from a central core (US 4,507,466). Typical dendrimers are based on polyamidoamine (PAMAM), polyethylene imine (PEI), polypropylene imine or polylysine. These synthetic macromolecules are assembled in a stepwise fashion, with each reaction cycle adding another layer of branches (dubbed generation"). Dendrimers are synthetically accessed by stepwise, divergentieribottom-up” or convergent Monttop-down" synthesis. Central structural component is the core unit from which hyperbranched dendrimers extend in a radially symmetric fashion.
  • the core may provide at least two reactive groups for dendrimer conjugation, it may also be of heterofunctional nature and protecting groups may be used.
  • the dendrimer may be assembled, and a guest compound may be subsequently conjugated to an anilin core by means of orthogonal chemistries (WO 88/01180).
  • the core and dendrimers form the interior or backbone of a dendrimer.
  • the terminal groups of the hyperbranches are defining the exterior.
  • the terminal branches form rather dense shells and flexible internal voids have been discovered.
  • Dendrimers are related to micelles, similary well suited to complex hydrophobic compounds. But in contrast they exhibit higher structural order because of their monomolecular nature and the absence of a dynamic equilibrium of various species. Synthetic compounds can only diffuse into dendrimers if certain structural requirement such as conformational rigidity and flatness as well as charge distribution such as affinity to tertiary amines are met.
  • apolar compounds such as pyrene or naphthalene have been encapsulated in dendrimers, but the number of trapped guests as well as their molecular interaction with the dendrimer interior are rater undefined and frequently substoichiometric.
  • the G4 dendrimers used for protein conjugation do not contain such voids. Furthermore it is apparent from molecular size comparison, that a 3 nm sized insulin may not be encapsulated in a dense, 4 nm-sized generation 4 PAMAM dendrimer. Hemoglobin has a diameter of 5.5 nm, and PAMAM dendrimers of G5, G6 and G7 exhibit diamters of 5.3 nm, 6.7 and 8.0 nm respectively. Macromolecules such as peptides and proteins are per se excluded from diffusion through the dense molecular packing and entering the interior of such dendrimers.
  • PAMAM dendrimers contain free amine groups on their surfaces and readily associate with DNA through electrostatic interactions.
  • WO 01/07469 details water-soluble polypeptide dendrimers constituted of ornithin and glycine amino acids.
  • the patent application also teaches the non-covalent encapsulation of an oligosaccharide, heparin, by dendrimerization of the dendrimer core in presence of heparin under mild conditions.
  • the oligosaccharide is released from the dendrimer by light-induced cleavage of UV-labile bonds within the dendritic backbone.
  • the core structure used here was tris(2-maleimidoethyl)amine. Presynthesized polypeptide dendrimers, containing a free thiol group were incubated in DMF in the presence of heparin.
  • the encapsulation should not alter the proteins' structure and properties and should efficiently protect the protein from attacks by the immune system and enzymes of the individual to which the protein is administered. Furthermore, the protein should enable an efficient release of the encapsulated protein, in case this is desired.
  • This object is attained by a protein encapsulated covalently or non-covalently by an encapsulating organic compound (EOC) wherein the protein and the encapsulating organic compound are present in 1:1 stoichiometry.
  • EOC encapsulating organic compound
  • EOCs are water soluble.
  • the EOCs contain several, i.e. at least 2, molecule chains of an appropriate length which chains can arrange such that a cavity is formed which can accommodate the protein and protect it from the action of enzymes, antibodies and the like.
  • the molecule chains will hereinafter be referred to as "encapsulating molecular chains" EMC.
  • the EMCs can be directly connected with each other, or via a chemical unit, often one or more so-called branching units (see below).
  • EMCs according to the present invention will be defined. This definition applies every time EMCs will be mentioned in the present application in a general form, either in connection wit a general formula or in any other context.
  • the EMCs contain hydrophilic groups, in an appropriate ratio and amount with respect to hydrophobic groups which may be present in the EOC, to render the latter water soluble.
  • Non- limiting examples of R include H, linear, branched or cyclical alkyl groups which may contain further functional groups or hetero atoms.
  • further groups known to the person skilled in the art can be present in the EMCs.
  • Example for preferred groups in the EMCs comprise oxyalkylene groups (i.e. oxyethylene (- OCH 2 CH 2 )-, oxypropylene groups (-OCH CH(CH 3 ))- and oxybutylene groups) and amide groups (-C(O)NH)-. It is preferred if the EMCs comprise oxyethylene groups (-OCH 2 CH 2 )- and amide groups (-C(O)NH)-.
  • the EMCs comprises at least one amino acid unit in its chain.
  • amino acid unit means an amino acid, preferably a naturally occurring amino acid like lysine, which is connected to at least one further binding partner, for example a further amino acid, by its amino and/or its carboxy function.
  • the amino acid may be modified, e.g. carry one or more substituents.
  • the EMCs can carry one or more substituents (capping groups or modifiers C) on their backbone.
  • Appropiate capping groups are sterically demanding groups.
  • the capping groups will in particular be present if the EMCs require sterically demanding groups forcing them into a certain conformation necessary for the creation of the cavity enclosing the protein.
  • the EMCs according to the present invention are not rigid, and the subunits of the EMCs may rotate around the bonds of the chain and occupy a spatial position in accordance with the sterical requirements (which, in general, will be the position with the lowest energy).
  • the capping groups can avoid a too close approaching of the EMCs and an opening of the cavity which may result in an insufficient encapsulating of the protein and an insufficient protection from the attack of enzymes, antibodies or the like. Furthermore, the protein may totally leave the cavity through the gap resulting from the movement of the EMCs.
  • the capping units comprise at least one amino acid unit in its chain.
  • amino acid unit means an amino acid, preferably a naturally occurring amino acid like lysine, which is connected to at least one further binding partner, for example a further amino acid, by its amino and/or its carboxy function.
  • the amino acid may be modified, e.g. carry one or more substituents.
  • the capping groups comprise oxyalkylene groups (i.e. oxyethylene (-OCH CH )-, oxypropylene groups (-OCH CH(CH 3 ))- and oxybutylene groups) and amide groups (-C(O)NH)-. It is even more preferred if the capping groups comprise oxyethylene groups (-OCH CH 2 )- and amide groups (-C(O)NH)-, in an appropriate ratio and amount, in order to obtain capping groups with the desired hydrophilicity which may be higher or lower than the hydrophilicity of the EMCs.
  • oxyalkylene groups i.e. oxyethylene (-OCH CH )-, oxypropylene groups (-OCH CH(CH 3 ))- and oxybutylene groups
  • amide groups -C(O)NH
  • the capping groups in the EMC can contain one or more functional groups from those cited above.
  • the functional groups present in a given capping group can be identical or different.
  • Each of the cited groups can be present only once or several times.
  • the capping groups present in a given EMC can be identical or different.
  • the capping groups do not have a high branching degree. This will in particular be the case if the EOCs according to the present invention have a high number of EMCs.
  • the capping groups are highly branched molecules having preferably a branching degree of 2, 3, 4, 5 or 6.
  • a branching degree of 2 means that the principal chain connected to the encapsulating unit splits up into 2 subchains, whereas in the case of a branching degree of 3, the main chain splits up into 3 subchains, etc.
  • the subchains may themselves also be branched. In the context of the present invention, this case will be referred to as "subbranched" (The modifiers are subbranched, i.e. their main chain contains subchains which themselves are branched.)
  • each of the 2 subchains can be subbranched to a subbranching degree of 2, meaning that also each of the 2 subchains into which the main chain (principal chain) splits up itself splits up into 2 subchains.
  • the branching degree will be designated as 2(2).
  • hyperbranched polymer used in this description is intended to include a combination of an EMC with capping groups as well as EOCs.
  • the encapsulation is realized by an EOC-protein inclusion compound EPIC according to the formula (I) in which the EMCs are connected to each other by one branching unit B, resulting in an EOC of the structure according to the formula (II) in which a cavity is formed.
  • branching unit (basic unit, core) containing at least one branching center Be and at least two branching functional groups Bfg connected to or capable of reacting with an encapsulating unit EMC;
  • EMC encapsulating molecular chain;
  • L linker containing at least one functional group Lfg which is connected to the protein P or capable of connecting with functional groups present on the protein P under the formation of a chemical bond; 1: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, preferably 3, 4, 5, 6, 7 or 8, in particular 2,3,4,5 or 6; P: pharmacologically active protein.
  • the EOCs according to the present invention may comprise more than 2 EMCs, for example 2, 3, 4 ,5 ,6 ,7, 8, 9, 10, 11, 12 or 13. In the formulae below, some preferred embodiments are shown.
  • the branching units B can be regarded as the basic unit or core of the EMCs according to the present invention.
  • the EMCs are linked by an EMC functional group to at least one branching unit B.
  • B contains at least one branching center Be.
  • Be include units like >CH- or >C ⁇ and the respective analogues wherein H is replaced by an organic group; >N-; >P-.
  • the centers Be can directly be linked to the branching functional groups (see below), or can be linked to at least one organic chain.
  • Examples for appropriate organic chains include linear, branched or cyclical alkyl chains. Hetero atoms like but not limited to S, N, O may be present within the chain.
  • Non-limiting examples of R include H, linear, branched or cyclical alkyl groups which may contain further functional groups or hetero atoms.
  • further groups known to the person skilled in the art can be present in B.
  • B can contain one or more groups chosen from those cited above.
  • the groups can be identical or different.
  • Each of the cited groups can be present only once or several times.
  • B comprises at least one amino acid unit, preferably of a naturally occurring amino acid like lysine. It is even more preferred if B contains a unit composed of several amino acid units.
  • B will be a branched structure containing one or more of the above mentioned groups and having a certain length, in accordance with the steric requirements of the protein to be encapsulated.
  • B will comprise one or more branching center.
  • B will contain at least two branching functional groups Bfg allowing for the attachment of the EMCs.
  • R include H, linear, branched or cyclical alkyl groups which may contain further functional groups
  • bond or “chemical bond” refers to the attraction forces as such between two or more atoms (e.g. a “covalent bond”), whereas “bond species” denotes the chemical bond and the atoms in the vicinity which is involved in the binding process (e.g.-S-S-).
  • the EMCs and B before forming the bond species both contain functional groups which are capable of reacting with each other under the formation of an appropriate chemical bond, preferably one of the bonds mentioned beforehand.
  • branching functional groups Bfg and EMC functional groups comprise amino (-NRH), carboxylic acid (-C(O)OH) and derivatives, sulfonic acid (-S(O) 2 - OH) and derivatives, carbonate (-O-C(O)-O-) and derivativs, hydroxyl (-OH), aldehyde (- CHO), ketone (-CRO), hydrazine (H 2 N-NR-), isocyanate (-NCO), isothiocyanate (-NCS), phosphoric acid (-O-P(O)(OR)OH) and derivatives, phosphonic acid (-P(O)(OR)OH) and derivatives, haloacetyl, alkyl halides, maleimide, acryloyl, arylating agents like aryl fluorides, hydroxylamine, disulfides like pyridyl disulfide, vinyl sulfone, vinyl ketone, diazoalkanes
  • branching functional groups and EMC functional groups comprise amino, carboxylic acid and derivatives, hydrazine, hydroxylamine, thiol, aldehyde, hydroxyl, carbonate, maleimide or haloacetyl groups.
  • B can contain two or more Bfgs. This is in particular the case when the EOC comprises more than four, for example 5, 6, 7, 8 or more EMCs.
  • B can contain one or more branching centers Be.
  • a further essential constituent of the EOCs according to the present invention is the linker L which serves to establish a chemical bond between the protein P and the EOC, by the reaction between appropriate functional groups Lfg on the linker L and the protein.
  • the chemical bond can be a covalent bond or a non-covalent bond, for example a coordinative bond.
  • the EOC has 1 or 2 linkers.
  • Non-cleavable linker a linker containing no selectively cleavable bonds.
  • Cleavable linker a linker containing a bond that can be selectively cleaved by a cleavage reagent (TCEP, TFA, DTT, enzyme, or a buffer).
  • TCEP cleavage reagent
  • Traceless linker a linker that upon cleavage releases protein in such a fashion that the protein is not associated with a remaining linker cleavage product.
  • Prodrug linker a cleavable linker containing a bond that can be selectively cleaved under in- vivo conditions, for instance in the presence of endogeneous enzymes or other endogeneous reagents, or solely in aqueous buffer.
  • Traceless prodrug linkers linkers having both the characteristics of prodrug linkers and traceless linkers.
  • the protein may need to be permanently encapsulated, and therefore non-cleavable stable linkers may be employed.
  • Hemoglobin requires the diffusion of oxygen through the EOC but the protein does not need to be released from its encapsulation for bioactivity.
  • Corresponding linkers are known in the art (Hermanson GT, Bioconjugate Techniques, Academic Press San Diego, 1996).
  • the release of the protein from the EOC/EPIC is mandatory for its bioactivity.
  • insulin In order to bind to its receptor, must diffuse out of the shielding EOC. Protein release may be achieved by cleaving the covalent tether between protein and EOC.
  • the linker L can react with any appropriate functional group Pfg present on the protein P, preferably with those mentioned below.
  • R include H, linear, branched or cyclical alkyl groups which may
  • bond or “chemical bond” refers to the attraction forces as such between two or more atoms (e.g. a “covalent bond”), whereas “bond species” denotes the chemical bond and the atoms in the vicinity which is involved in the binding process (e.g.-S-S-).
  • the bond species depicted beforehand are formed by the reaction between functional groups (which functional groups can be identical or different), the EOC, before reacting with the protein, and the protein, before reacting with the EOC, both contain functional groups which are capable of reacting with each other under the formation of an appropriate chemical bond, preferably one of the bonds mentioned beforehand.
  • Pfg protein functional groups
  • Pfgs comprise amino, imidazole and thiol groups.
  • linker functional groups comprise amino (-NRH), carboxylic acid (- C(O)OH) and derivatives, sulfonic acid (-S(O) 2 -OH) and derivatives, carbonate (-O-C(O)-O-) and derivatives, hydroxyl (-OH), aldehyde (-CHO), ketone (-CRO), isocyanate (-NCO), isothiocyanate (-NCS), haloacetyl, alkyl halides, maleimide, acryloyl, arylating agents like aryl fluorides, disulfides like pyridyl disulfide, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, epoxide, oxirane, aziridine,
  • R include H, linear, branched or cyclical alkyl groups which may contain further functional groups or hetero atoms or aryl groups.
  • Lfgs comprise carbamate, carbonate, thiol, thioether, succinimidyl, amide and disulfide.
  • a part of the present invention are traceless double prodrug linker structures and their EPICs resulting in a novel mechanism of cleavage and subsequent release of the protein from the EOC.
  • linker reagents cleave in such a fashion, that part of the linker remains conjugated to the protein.
  • linker fragments are of low molecular weight and if the site of conjugation does not involve an amino acid that is essential for receptor binding, the bioactivity of the therapeutic protein may be fully or partially retained.
  • More advantageous are cleavable, traceless linkers that release the protein in an unmodified form under in vivo conditions such as neutral pH without the addition of chemical or biological cleaving agents. Examples are double prodrugs which are based on linker moieties which are cleaved in a two-step process in vivo.
  • WO 99/30727A1 which is incorporated herein by reference, reveals conjugates containing a PEG moiety, a double prodrug linker and protein.
  • the advantage of such systems is that the protein is released in an unmodified form.
  • the linker cleavage process is traceless, the protein end product of the cleavage step do not contain remnants of the linker structure.
  • one bond is hydrolyzed. This is typically an ester bond, such as in a phenol ester, and hydrolysis may occur by enzymatic attack (upases) or autohydrolysis or a combination of both.
  • the resulting free phenol is instable and rapidly rearranges for instance through 1,4- or 1,6-arylelimination, and cleavage of a carbamate releases the protein, CO 2 and an instable aromatic moiety.
  • linker are known to the person skilled in the art that can be cleaved in such a fashion that after cleavage no parts of the linker remain at the EOC.
  • a preferred embodiment of the present invention are traceless prodrug linkers which contain an ester functionality, in particular a phenol ester functionality, and a carbamate functionality.
  • linker reagents examples are those according to the formulae (1), (2), (5), (6) and (7).
  • linker reagent is the linker reagent according to the formula (11) below (traceless prodrug linker).
  • the protein can be encapsulated entirely or partially by the EOC. It is preferred to encapsulate the protein entirely, i.e. the cavity is of a size sufficiently large to accept the entire protein therein.
  • the EPICs according to the present invention can, in principle, accommodate any protein which has a physiological or pharmacological activity. These are known to the person skilled in the art. Important proteins can be found in standard text books which are known to the skilled artisan.
  • therapeutic proteins and polypeptides which can be encapsulated according to the present invention are: ACTH, adenosine deaminase, agalsidase, albumin, alfa-1 antitrypsin (AAT), alfa-1 proteinase inhibitor (API),reteplase, anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal, and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, biphalin, bone-morphogenic proteins, calcitonin (salmon), collagenase, DNase, endorphins, enfuvirtide, enkephalins, erythropoietins, factor Vila, factor VIII, factor Villa, factor IX, fibrinolysin, fusion proteins, follicle-stimulating hormones, granulocyte colony stimulating factor (G-CSF), galact
  • Preferred proteins are antibodies, calcitonin, G-CSF, GM-CSF, erythropoietins, hemoglobins, interleukins, insulins, interferons, SOD, somatropin, TNF, TNF-receptor-IgG Fc.
  • the most preferred proteins are erythropoietins, interferons, insulins, somatropins and hemoglobins.
  • the invention is not restricted to therapeutic proteins. Protection from aggressive environments is also desirable for other proteins such as amylases, proteases, peptidases, xylanases, lipases, lipoxygenases, cellulases, pectinases, phytases, oxidoreductases applied in industrial processes such as food and animal feed applications, as cleaning compounds in laundry detergents, dishwashing detergents, in the manufacture of chemicals such as alcohol, steroids and antibiotics, amino acids, proteins, trigylcerides, phospholipids, and for textile, leather and fur applications, especially in the prebleaching of pulp.
  • proteins such as amylases, proteases, peptidases, xylanases, lipases, lipoxygenases, cellulases, pectinases, phytases, oxidoreductases applied in industrial processes such as food and animal feed applications, as cleaning compounds in laundry detergents, dishwashing detergents, in the manufacture of chemicals such as alcohol, steroids and antibiotics,
  • All proteins in particular those cited beforehand, can be encapsulated in a macrocyclic structure according to the present invention, to result in an MPIC, or in a dendrimer resulting in a DPIC.
  • the size of the cavity in the EOCs (i.e. the proteophors, macrocyclic structures and dendrimers) according to the present invention needs to be adapted to the proteins diameter.
  • the size should be larger than the diameter of the smallest sphere that can be drawn around a correctly folded protein. From this diameter estimation, the length of the corresponding molecular chain in the EOC host can be calculated.
  • a chain of at least 5 nm length that can fold into a halfcyclic conformation needs to be present in the EOC.
  • the EMCs according to the formula (II) contain capping groups (C) which are arranged such that a dendritic structure of the EOC results.
  • C capping groups
  • DPIC dendrimer-protein inclusion compounds
  • Embodiments of the capped EOCs having three and four EMCs are shown in the formulae (VII) and (VIII) below.
  • the DPICs according to the general formulae (V) to (VIII) show a 1:1 ratio protein/dendrimer.
  • the DPICs are soluble in water.
  • the cavity of the dendrimer also comprises water, in addition to the protein.
  • Dendrimers are known to the person skilled in the art. Reference is made to: Dendrimer II Architecture, Nanostructure and Supramolecular Chemistry, Springer Verlag 2000, F. V ⁇ gtle Editor. Dendrimers are based on repeating hyperbranched structures emanating from a central core (US 4,507,466). These synthetic macromolecules are assembled in a stepwise fashion, with each reaction cycle adding another layer of branches (dubbed generation"). Dendrimers are synthetically accessed by stepwise, divergentieribottom-up” or convergent Monttop-down" synthesis. Central structural component is the core unit from which hyperbranched dendrimers extend in a radially symmetric fashion.
  • the dendrimers according to the present invention may contain, in the capping groups, centers branching into two, three, four, or more directions, preferably two.
  • the length of dendritic chains may be identical or vary between chains of one dendrimer. Preferred chain lengths for individual dendrimers are up to 5000 bonds.
  • capping groups By the choice of appropriate capping groups, it is perfectly possible to protect the encapsulated protein form the attack of e.g. antibodies or the elimination by the kidney or the liver.
  • the capping groups C have been defined above, which definition also applies here.
  • an EMC can carry one capping group C (as shown in the formulae) or more than one, i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or even more capping groups C.
  • some capping groups in dendrimers according to the invention contain branched heterofunctional units carrying at least one thio- succinimido moiety.
  • Thio-succinimido groups are the result of a reaction between a maleimido and a thiol group and can be obtained under mild conditions, proving useful for the synthesis of hyperbranched or dendritic structures.
  • Further units which can be used in the synthesis of the dendrimers according to the present invention comprise tris-(2- maleimidoethyl)amine and hydroxysuccinimide ester (EP-A 0 618 192).
  • the dendrimers according to the present invention can efficiently be formed of multidentate compounds containing only one maleimide group and a number of protected thiols, in a divergent synthesis approach.
  • the monomaleimido-tetrathio-dendrimer compounds according to the present invention are of the general formula M-A-(S-Pg) n , with the following meanings: M: maleimido, A: spacer, S: sulfur, Pg: thiol protecting group, n: 2 to 200.
  • Suitable thiol protecting groups benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl-, 2,4,6- trimethoxybenzyl-(Tmob), 4,4'-dimethoxyphenylmethyl-(diMpm), trityl-, 4-methoxytrityl- (Mmt), 4,4'-dimethoxytrithyl- (DMTr), 4,4',4"-trimethoxytrityl- (TMTr), tert.-butyl- MeCONHCH2- (Acm), PhCH2CONHCH2- (PhAcm), MeOCOS- (Scm), BzlOCOS- (SZ) PhN(Me)COS- (Snm), TrtS-, 2-pyridinesulfenyl-, 2-(3-nitropyridinesulfenyl), 4,5,6- trimethoxy-2,3-dihydro-7-benzofuranylmethyl- (Tm
  • Multidentate compounds are water soluble and the conjugation reactions will not compromise the biomolecule's structural integrity or bioactivity.
  • the core of the DPIC is formed by the protein to be encapsulated which is connected (conjugated) to the polymer backbone by a suitable linker, in general one of the linkers listed above.
  • a DPIC results in which the protein is not connected to the dendrimer via a linker (a chemical bond), but the protein is held within the cavity defined by the dendrimer.
  • the resulting DPICs are an object of the present invention. It depends on the release kinetics of the protein if the DPIC having no bond between the protein and the dendrimer can be isolated as such.
  • the EOCs comprise a second branching group B identical or different from the first branching group B to which the EMCs are connected, resulting in a cavity which is horizontally locked and vertically open.
  • the encapsulation is realized by a macrocycle-protein inclusion compound MPIC according to the formula (IX)
  • B branching unit (basic unit, core) containing at least one branching center Be and at least two branching functional groups Bfg connected to or capable of reacting with an encapsulating unit EMC;
  • EMC encapsulating molecular chain;
  • L linker containing at least one functional group Lfg which is connected to the protein P or capable of connecting with functional groups present on the protein P under the formation of a chemical bond; 1: 1, 2, 3, 4, 5, 6, 7, 8 or 9, preferably 1, 2, 3, 4 or 5, in particular 1, 2 or 3;
  • the MPICs according to the general formula (IX) show a 1:1 ratio protein/macrocyclic structure.
  • the MPICs are soluble in water.
  • the cavity of the macrocyclic structure also comprises water, in addition to the protein.
  • the EMCs contain hydrophilic groups, in an appropriate ratio and amount with respect to hydrophobic groups which may be present in the macrocyclic structure, to render the latter water soluble.
  • Some embodiments are depicted in the formulae (XI) and (XII) below.
  • the EMCs can all be identical, partly identical (partly different) or entirely different from each other.
  • the EMCs can carry capping groups C, as defined above, on their backbone. Appropiate capping groups are sterically demanding groups.
  • the macrocyclic structures of the present invention are not rigid, and the EMCs, due to the rotation around the bonds connecting them to the branching units B, may swing to one side, resulting in a staggering and crowding on one side of the macrocyclic structure, and opening of one or more sides of the cavity. Capping groups prevent sterical proximity of the EMCs. If the EMCs come too close to one another, insufficient protection of the encapsulated protein from the attack of enzymes, antibodies or the like may result. Furthermore, the protein may leave the cavity (if the linker is broken) through the gap, resulting in an undesired release kinetics of the protein. In case capping groups are present, the following structures (XIII) and (XIV) result.
  • an EMC can carry one capping group C (as shown in the formulae) or more than one, i.e. 2, 3, 4, 5 or even more capping groups C.
  • Examples for EPICs, DPICs and MPICs wherein the linker has been cleaved and the protein is not held within the cavity by covalent bonds are depicted in the formulae (XVII) to (XX) below, which include examples in which traces of the linker remain at the EOC, dendrimer or macrocyclic structure, and examples wherein the linker has totally been removed.
  • Modified proteins containing a linker are a part of the present invention.
  • the linker is a prodrug linker or a traceless linker, more preferably traceless prodrug linker.
  • a MPIC results in which the protein is not connected to the macrocyclic structure via a linker (a chemical bond), but the protein is held within the cavity defined by the macrocyclic structure.
  • the resulting MPICs are an object of the present invention. It depends on the release kinetics of the protein if the MPIC having no bond between the protein and the macrocyclic structure can be isolated as such.
  • the EPICs, MPICs and the DPICs of the present invention are synthesized from the protein and the EOC, macrocyclic structure and dendrimer, respectively, by a combination of solid- phase and solution synthesis methods known to the person skilled in the art.
  • the host molecule may be equipped with the linker moiety and be attached to the protein in one single reaction step (convergent synthesis).
  • the linker-protein conjugate may be reacted with the branching unit B contained in the EOC, dendrimer or macrocyclic backbone structure.
  • protein-linker- branching unit conjugate is reacted with presynthesized EOCs, macrocyclic structures or dendrimers.
  • the dendrimers, macrocyclic structures or EOCs are assembled in a stepwise fashion in an extension of the central protein-linker- branching unit structure.
  • Antibodies against therapeutic proteins are high-affinity, high-selectivity probes. Steric shielding of the protein prevents access of the antibodies to the epitopes for molecular recognition.
  • Antibody binding may be conveniently and reliably measured by methods known to the person skilled in the art, preferably immunoprecipitation or, as exemplified here, by label-free surface plasmon resonance scanning.
  • various insulin derivatives including insulins conjugated to different PEG reagents, and three monoclonal anti-insulins
  • complete prevention of antibody recognition was only achieved if insulin was complexed with a macrocyclic structure according to the present invention.
  • non-cleavable covalent PEG or EOC conjugates were employed respectively.
  • the resulting EOC self-organizes into a biomolecule-containing void by conformationally folding around the protein. This arrangement may be driven by sterical constraints or by chemical reactions or both.
  • Linker cleavage may be performed in vitro to generate a non-covalent complex.
  • linker cleavage may occur in a prodrug approach in vivo after administration.
  • Dissociation kinetics of the complex may be governed by linker hydrolysis or protein effusion through the molecular matrix of the EOC, dendrimer, or macrocyclic structure, or a combination of both.
  • the complex In the presence of the protein, the complex is characterized by a well-defined cavity-forming chemical structure and precise stoichiometry. After protein release, the host molecule may adopt various conformations due to its structural flexibility, for which reason protein release is essentially irreversible.
  • the present invention also relates to method for selectively delivering a protein to a target, which method comprises providing an encapsulated protein; bringing the encapsulated protein into contact with a body liquid containing the target.
  • the encapsulated protein can be formulated into a drug, optionally together with one or more pharmaceutically acceptable carriers.
  • the drug can contain one or more encapsulated protein types.
  • Drug containing at least one encapsulated protein according to the present invention and optionally one or more pharmaceutically acceptable carriers are also an object of the present invention
  • Fig. 1 Size exclusion chromatograms of a) native Hb, b) 39, c) reaction mixture 40, and d) purified covalent Hemoglobin MPIC 40. UV signals were recorded at 280 nm.
  • Fig. 2 Size exclusion chromatograms of a) 41, b) 42 and c) Hb released from 42. UV signals were recorded at 280 nm.
  • Fig. 3 Size exclusion chromatograms of a) reaction mixture resulting from linker cleavage procedure performed on 50a, b) Insulin MPIC 50a. UV signals were recorded at 280 nm.
  • Fig. 4 In vitro release of insulin from Insulin MPIC 64 or 65, respectively. Kinetics were determined by HPLC using UV detection at 215 nm.
  • Fig. 5 Release of insulin from dendrimer prodrugs 90 (top) and 91 (below). Free insulin was quantified by HPLC using UV detection at 215 nm.
  • Fig. 6 Binding of insulin or insulin conjugates to immobilized murine anti insulin antibodies (clones 8E2, C7C9 and 7F8).
  • Fmoc-amino acids, resins and TBTU were purchased from Novabiochem and are named according to the catalogue. Fmoc-Ado-OH was obtained from Neosystem (France) and Fmoc- PP-OH from Polypure (Norway). All additional chemicals were purchased from Sigma Aldrich. Human insulin was from ICN Biomedicals (USA). Maleimide-PEG5k, Maleimide- PEG20k and Maleimide-PEG2x20k were obtained from Nektar. Reaction medium Solid phase synthesis was performed on TentaGel TGR or Sieber amide resin with a loading of 0.2 mmol/g or 0.5 mmol/g, respectively. Syringes equipped with polypropylene frits were used as reaction vessels. Standard coupling cycle for Fmoc-protected amino acids
  • resin was repeatedly (three times, 4 min each) agitated with 2/2/96 (v/v/v) piperidine/DBU/DMF and repeatedly (six times) washed with DMF.
  • Coupling of Fmoc-protected amino acids to resin was achieved by agitating the resin with 3 equivalents (eq) of Fmoc-amino acid, 3 eq TBTU and 6 eq DIEA in DMF for 60 min. Finally, the resin was repeatedly (five times) washed with DMF.
  • Mass spectrometry was performed on a waters ZQ 4000 ESI instrument and spectra were, if necessary, interpreted by waters software MaxEnt.
  • TentaGel TGR resin was soaked in THF and incubated for 60 min with a solution of 4 ml of 0.5 M chloroformic acid-4-nitrophenyl ester and 0.5 M DIEA in THF, washed with THF and dried. 4 ml of a suspension of 0.3 M cystamine-dihydrochloride and 0.7 M DIEA in DMSO were added to the resin and agitated for 90 min. Resin was washed with DMSO and DMF, and 3 eq maleimidopropionic acid and 3 eq DIC in DMF were added and agitated for 60 min.
  • Cystamine-dihydrochloride was suspended in 1/1 (v/v) DMSO/DMF and mixed with 2 eq maleimidopropionic acid, 2 eq DIC and 2 eq DIEA. The suspension was agitated for 2 h at room temperature (RT) and after acidification with formic acid, compound 2 was purified by RP-HPLC.
  • Cysteamine hydrochloride was dissolved in TFA and 0.5 eq Mmt-chloride were added. After 30 min, TFA was removed under nitrogen flow and the residue was taken up in pyridine. After adding a solution of 0.2 M Na 2 CO 3 , product was extracted with ether and dried over Na 2 SO 4 . Following filtration, solvents were removed using a rotary evaporator and compound 3 was obtained as a highly viscous oil.
  • Resin was washed with THF and DMF and agitated for 30 min with a solution of 1 M cystamine in DMF and washed with DMF. Subsequently, resin was agitated for 15 min in a solution of 2/1/1 (v/v/v) DMF/acetic anhydride/pyridine. After washing the resin with DMF and DCM, compound 7 was cleaved by agitation for 30 min in 10 ml of 4/1 (v/v) DCM/TFA. After evaporation of solvent under nitrogen flow, product 7 was purified by RP- HPLC.
  • Fmoc-Lys(Mtt)-OH, Fmoc-Lys(Fmoc)-OH and Fmoc-PP-OH were coupled according to the standard protocol for solid phase synthesis. After Fmoc removal, resin was incubated with 6 eq maleimidopropionic acid and 6 eq DIC for 30 min. Following cleavage from resin, compound 20 was purified by RP-HPLC.
  • MS (MW calculated) 24a 7719 g/mol (7722 g/mol)
  • MS (MW calculated) 24b 10120 g/mol (10121 g/mol)
  • Compound 26 was obtained according to the standard protocol for solid phase synthesis.
  • the amino acids Fmoc-Cys(StBu)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-PP-OH, Fmoc-Lys(Boc)- OH, Fmoc-PP-OH and Fmoc-Cys(Mmt) were coupled to Sieber amide resin. After final Fmoc-removal, resin was treated with a solution of 2/1/1 (v/v/v) DMF/acetic acid anhydride/pyridine for 15 min, washed with dichloromethane and dried in vacuo.
  • Compound 27 was obtained according to the standard protocol for solid phase synthesis. Starting from Sieber amide resin, the amino acid sequence Fmoc-Lys(Mtt)-OH, Fmoc- Lys(Fmoc)-OH, Fmoc-PP-OH, Fmoc-Lys(Boc)-OH, Fmoc-PP-OH and Fmoc-Lys(Boc)-OH was assembled. After final Fmoc-removal, the resin was reacted for 30 min with 6 eq maleimidopropionic acid and 6 eq DIC, washed with dichloromethane and dried in vacuo.
  • Compound 28 was obtained from educts 26 and 27 in analogy to the synthesis of 24 from educts 20 and 21 according to protocol II-3. Cyclization of 28 to 29 was performed in analogy to cyclization of compound 16 according to protocol II-l. For analysis, a sample was treated with TFA to effect removal of the Boc-protecting groups.
  • MS (MW calculated without Boc-groups) 29: 14717 g/mol (14720 g/mol) 29 were reacted with 10 eq 6 and 10 eq DIC in DMF for 30min. Product was purified by RP- HPLC and lyophilized.
  • Compound 35 was obtained according to the standard protocol for solid phase synthesis.
  • the amino acids Fmoc-Lys(Boc)-OH, Fmoc-Lys(Fmoc)-OH and Fmoc-Lys(Fmoc)-OH were coupled to TGR resin, and Mmt-3-mercaptopropionic (8) acid was used as the terminal building block. After resin cleavage, product was purified by RP-HPLC.
  • Compound 38 was obtained according to the standard protocol for solid phase synthesis.
  • the amino acids Fmoc-Dpr(ivDde)-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-Lys(Fmoc)-OH and two units of Fmoc-PP-OH were coupled to TGR resin.
  • resin was incubated with a solution of 2/1/1 (v/v/v) DMF/acetic acid anhydride/pyridine for 15 min. Removal of the ivDde-protecting group was afforded by repeatedly agitating (three times) the resin for 5 min with 98/2 (v/v) DMF/hydrazine.
  • the resin was washed with DMF and treated for 30 min with a solution of 6 eq maleimidopropionic acid and 6 eq DIC in DMF. After cleavage from the resin the product was purified by RP-HPLC.
  • Hb MPIC 40 was purified by SEC (Superdex 200 column).
  • Figure 1 displays size exclusion chromatograms of native Hb, 39, the reaction mixture of 39 and Hb, and purified product 40.
  • Hb was adjusted to a concentration of 10 mg/ml in 0.1 M sodium phosphate buffer (pH 7.5). After addition of 10 eq 2 the solution was agitated for 30 min at RT. Hb-conjugate 41 was purified by SEC (Superdex 200).
  • the concentration of 41 was adjusted to 20 ⁇ M in 0.1 M phosphate buffer (pH 7.5). After addition of 2 eq 19 the solution was incubated for 45 min at RT.
  • the Hemoglobin MPIC 42 was purified by SEC (Superdex 200).
  • product 42 was treated with 5 mM TCEP in 0.1 M phosphate buffer (pH 7.5). The quantitative release of Hb from the MPIC was assessed by LC/MS.
  • Figure 2 displays size exclusion chromatograms of 41, 42 and of Hb (44) released from 42.
  • Structural element 37' represents the succinimidyl-containing product of the Michael addition of the neighboring proteophore thiol to the maleimido group of 37.
  • Compound 45 was reacted with 30 eq 37 for 1 h at RT in 50 mM sodium phosphate buffer (pH 7.0) and purified by SEC (Superdex 200, flow rate: 0.75 ml/min).
  • Insulin was released from conjugates 50a or 50b 3 respectively, by cleavage of the linker moieties by incubation with 1:1 (v/v) DCM/TFA for 15 min. These conditions also effected removal of the Boc-protection group on the ⁇ -Aminoany of the insulin A-chain.
  • Educts 50a and 50b, linker cleavage mixtures containing released insulin and remaining macrocyclic structures 52a and 52b were characterized by SEC (Superdex 200, flow rate: 0.75 ml/min).
  • Figure 3 displays size exclusion chromatograms of 50a and products of the linker cleavage procedure. Three peaks were detected and identified by LCMS analysis. The peak at retention time 23.2 min contains insulin, the peak at 21.6 min is EOC 52a. The peak at retention time 20.7 min corresponds to EOC-insulin-monoconjugate.
  • Trt-protecting groups from compound 55 was effected by incubation for 30 min in 2/58/40 (v/v/v) TES/TFA/DCM.
  • Structural element R represents the succinimidyl-containing product of the Michael addition of the neighboring proteophore thiol to the maleimido group of 37, 38 or N-ethyl maleimide, respectively.
  • Aliquots (60 nmol) of compound 56 were reacted with 10 eq N-ethyl-maleimide, or 37 or 38, respectively, for 15 min in 500 ⁇ l 1/4 (v/v) acetonitrile/100 mM phosphate buffer (pH 8.0).
  • Subsequent purification by SEC Superdex 200, flow rate: 0.75 ml/min yielded products 57, 58 or 59, respectively.
  • Trt-protection of 60 was afforded by stirring the compound in TFA/TES 95/5 (v/v) for 10 min at RT. The solution was dried under nitrogen flow. The residue was incubated for 30 min at RT in 1/1 TFA/DCM (v/v) and solvent was removed by a nitrogen flow. Product 61 was purified by RP-HPLC.
  • Structural element R represents the succinimidyl-containing product of the Michael addition of the neighboring proteophore thiol to the maleimido group of compound 37 or N-ethyl- maleimide, respectively.
  • Structural element R represents the succinimidyl-containing product of the Michael addition of a thiol to the maleimido group of compound 37, N-ethyl-maleimide, Maleimide-PEG5k, Maleimide-PEG20k or Maleimide-PEG2x20k, respectively.
  • Thiols are associated with the modified insulins 54 or 67, respectively.
  • Resin was treated with DMF/hydrazine 98/2 (v/v), washed and agitated with 5 eq maleimidopropionic acid and 5 eq DIC in DMF for 30 min.
  • Product was cleaved from resin with TFA/TES/water 95/3/2 (v/v/v). After evaporation of solvent, the residue was taken up in 3/1 (v/v) DMF/collidine and reacted for 30 min with a solution of 15 eq 8 preactivated for 15 min with 10 eq DIC in DMF. After acidification with acetic acid, product 77 was purified by RP-HPLC.
  • Structural element 77' represents the succinimidyl-containing product of the Michael addition of a thiol group to the maleimido group of compound 77 after Mmt protecting group removal.
  • Thiol groups are either associated with the insulin-linker conjugate or with a dendron-insulin conjugate.
  • Structural element R represents the succinimidyl-containing product of the Michael addition of a thiol group of 77' to the maleimido group of compound 37, 38, N-ethyl-maleimide, or Maleimide-PEG5k, respectively.
  • Structural element 77' represents the succinimidyl-containing product of the Michael addition of a thiol group to the maleimido group of compound 77 after Mmt protecting group removal.
  • Thiol groups are either associated with the insulin-linker conjugate or with a dendron-insulin conjugate.
  • Insulin in DMSO was mixed with a solution of 0.9 eq 11 in DMSO.
  • the resulting solution was adjusted to pH 8.0 with DIEA and stirred for 1.5 h at RT.
  • RP-HPLC purification gave Mmt-protected intermediate 85.
  • Regioselectivity of the monoconjugation was determined by reduction of 85 with DTT (10 mM) in 0.5 M phosphate buffer pH 8.0 for 1 h at RT and subsequent analysis of the insulin A- and B-chains by LC-MS. After lyophilization, compound 85 was mixed with 95:5 (v/v) TFA/triethylsilane and stirred for 5 min. Nolatiles were removed under nitrogen flow and 86 was purified by RP-HPLC and lyophilized.
  • Structural element 37' represents the succinimidyl-containing product of the Michael addition of a thiol group to the maleimido group of compound 37.
  • Thiol groups are associated with a generation 1 dendron-insulin conjugate.
  • 50 ⁇ l of a solution of 87 (450 ⁇ M) in 1/1 acetonitrile/water were mixed with 3.5 mg of 37.
  • the pH was adjusted to 7.5 with 0.5 M phosphate buffer (pH 7.5) and the solution was incubated for 30 min at RT. Purification by SEC (Superdex 200, flow rate 0.75 ml/min) gave compound 90.
  • Structural element 37' represents the succinimidyl-containing product of the Michael addition of a thiol group to the maleimido group of compound 37.
  • Thiol groups are associated with a generation 2 dendron-insulin conjugate.
  • a sensor chip was mounted to the instrument and RAMFc (rabbit anti mouse Fc antibody, BIAcore) was immobilized according to Karlsson et al. (J. Immun. Meth, 200, 1997, 121-133) using EDC/NHS activation. Capping of activated, unreacted surface carboxy groups was effected by ethanolamine.
  • RAMFc rabbit anti mouse Fc antibody, BIAcore
  • Insulin and insulin conjugates 68-75, 57-59 and 81-84 were subject to analysis.
  • standard flow buffer containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0,005 % Tween 20.
  • Three urine anti insulin monoclonal antibodies (Advanced ImmunoChemical Inc., clones C7C9, 8E2, or 7F8, respectively,) were loaded onto prespecified sensor chip areas by injection of 15 ⁇ l of a solution of 30 ⁇ g/ml. A fourth sensor area was used for reference purposes. After equilibration for 2.5 min, 150 ⁇ l of a 100 nM solution of insulin or insulin conjugate were injected and flowed across all four sensor areas. A dissociation phase of 3 min was followed by removal of the anti-insulins by injection of 60 ⁇ l glycine buffer (pH 2.0) and regeneration of the sensor chip surface. Encapsulation efficiency was measured by recording the refractive index units (RU) of each of the four sensor areas before dissociation.
  • RU refractive index units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
EP04765740.8A 2003-10-02 2004-10-01 Hyperverzweigte polymer-Konjugate über nichtenzymatisch spaltbare Verbindungsglieder Expired - Lifetime EP1682186B1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP04765740.8A EP1682186B1 (de) 2003-10-02 2004-10-01 Hyperverzweigte polymer-Konjugate über nichtenzymatisch spaltbare Verbindungsglieder
EP16160207.3A EP3085388B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten polymeren via nicht-enzymatisch spaltbaren verbindungsgliedern
DK09161150.9T DK2090323T3 (en) 2003-10-02 2004-10-01 Hyperbranched polymer conjugate via non-enzymatically cleavable linkers
EP09161150.9A EP2090323B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten Polymeren via nicht-enzymatisch spaltbaren Verbindungsgliedern
CY20141100190T CY1114972T1 (el) 2003-10-02 2014-03-07 Υπερ-διακλαδισμενα συζευγματα πολυμερους μεσω ενος μη ενζυμικως διασπασιμου συνδετη
CY20161101093T CY1119457T1 (el) 2003-10-02 2016-10-27 Υπερδιακλαδισμενα συζευγματα πολυμερων μεσω μη ενζυματικου συνδετη με δυνατοτητα σχασης

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03022097A EP1525890A1 (de) 2003-10-02 2003-10-02 Protein-Proteophor Komplex
EP04765740.8A EP1682186B1 (de) 2003-10-02 2004-10-01 Hyperverzweigte polymer-Konjugate über nichtenzymatisch spaltbare Verbindungsglieder
PCT/EP2004/010973 WO2005034909A2 (en) 2003-10-02 2004-10-01 Hyperbranched polymer conjugates via non-enzymatic cleavable linker

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP16160207.3A Division EP3085388B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten polymeren via nicht-enzymatisch spaltbaren verbindungsgliedern
EP09161150.9A Division EP2090323B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten Polymeren via nicht-enzymatisch spaltbaren Verbindungsgliedern
EP09161150.9 Division-Into 2009-05-26

Publications (2)

Publication Number Publication Date
EP1682186A2 true EP1682186A2 (de) 2006-07-26
EP1682186B1 EP1682186B1 (de) 2013-12-11

Family

ID=34384573

Family Applications (4)

Application Number Title Priority Date Filing Date
EP03022097A Withdrawn EP1525890A1 (de) 2003-10-02 2003-10-02 Protein-Proteophor Komplex
EP04765740.8A Expired - Lifetime EP1682186B1 (de) 2003-10-02 2004-10-01 Hyperverzweigte polymer-Konjugate über nichtenzymatisch spaltbare Verbindungsglieder
EP16160207.3A Expired - Lifetime EP3085388B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten polymeren via nicht-enzymatisch spaltbaren verbindungsgliedern
EP09161150.9A Expired - Lifetime EP2090323B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten Polymeren via nicht-enzymatisch spaltbaren Verbindungsgliedern

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03022097A Withdrawn EP1525890A1 (de) 2003-10-02 2003-10-02 Protein-Proteophor Komplex

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP16160207.3A Expired - Lifetime EP3085388B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten polymeren via nicht-enzymatisch spaltbaren verbindungsgliedern
EP09161150.9A Expired - Lifetime EP2090323B1 (de) 2003-10-02 2004-10-01 Konjugate von stark verzweigten Polymeren via nicht-enzymatisch spaltbaren Verbindungsgliedern

Country Status (10)

Country Link
US (2) US7879588B2 (de)
EP (4) EP1525890A1 (de)
CY (2) CY1114972T1 (de)
DK (2) DK2090323T3 (de)
ES (2) ES2600729T3 (de)
HU (1) HUE030243T2 (de)
PL (1) PL2090323T3 (de)
PT (1) PT2090323T (de)
SI (1) SI2090323T1 (de)
WO (1) WO2005034909A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE464123T1 (de) * 1997-06-20 2010-04-15 Univ New York Elektrosprühen von lösungen zur massenherstellung von chips und molekülbibliotheken
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP3332811A1 (de) 2002-09-06 2018-06-13 Cerulean Pharma Inc. Cyclodextrinbasierte polymere zur bereitstellung des kovalent daran gebundenen camptothecins
US8377917B2 (en) * 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP2111872B1 (de) * 2004-07-05 2020-12-23 Ascendis Pharma GmbH Hydrogel-konjugate
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (de) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel Polymer Prodroge Konjugate
US7341720B2 (en) 2005-04-06 2008-03-11 Genzyme Corporation Targeting of glycoprotein therapeutics
CA2627459C (en) * 2005-10-25 2011-08-09 Evonik Degussa Gmbh Preparations containing hyperbranched polymers
CA2629300C (en) 2005-11-17 2014-07-08 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
TWI528976B (zh) * 2006-12-13 2016-04-11 斯茹林製藥公司 用於醫物傳遞之以環糊精為基之聚合物
CN101631794B (zh) 2007-01-18 2013-01-02 建新公司 包含氨基氧基基团的寡糖及其轭合物
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
EP1982698A1 (de) * 2007-04-18 2008-10-22 Evonik Degussa GmbH Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
CA2701291A1 (en) 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
CA2722743A1 (en) 2008-04-28 2009-11-05 Zogenix, Inc. Novel formulations for treatment of migraine
EP2113256A1 (de) 2008-04-29 2009-11-04 Ascendis Pharma AS Pegylierte rhGH-Verbindungen
HUE054585T2 (hu) 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
DE102008042923A1 (de) 2008-10-17 2010-04-22 Evonik Goldschmidt Gmbh Präparate zur gesteuerten Freisetzung von Wirkstoffen
CN103432566A (zh) 2008-12-16 2013-12-11 建新公司 寡糖-蛋白缀合物
EP2403537A1 (de) 2009-03-05 2012-01-11 Ascendis Pharma A/S Interferon-alpha-träger-prodrugs
RU2573911C2 (ru) 2009-05-20 2016-01-27 Байомарин Фармасьютикал Инк. Варианты натрийуретического пептида с-типа
AU2010277559B2 (en) 2009-07-31 2016-08-11 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
MA33466B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Composition d'insuline à longue duree d'action
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010311421B2 (en) 2009-10-29 2014-11-20 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
FR2955111B1 (fr) * 2010-01-12 2013-05-31 Biomerieux Sa Procede de preparation de composes polybiotinyles
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525830B1 (de) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptidbasierte prodrug-linker für aliphatische aminhaltige arzneimittel
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US20130216593A1 (en) * 2010-08-28 2013-08-22 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for plasmid gene transfection using polymer-modified microbubbles
EP2438930A1 (de) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrug mit einem exendinbindenden Konjugat
EP2592103A1 (de) 2011-11-08 2013-05-15 Adriacell S.p.A. Polymeraldehydderivate
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US20170081573A1 (en) * 2014-05-23 2017-03-23 3M Innovative Properties Company A Discontinuous Silicone Adhesive Article
HRP20211734T8 (hr) 2014-11-21 2022-03-04 Ascendis Pharma Endocrinology Division A/S Dozni oblici dugodjelujućeg hormona rasta
US20200188524A1 (en) * 2016-09-22 2020-06-18 University Of Washington Molecular logic gates for controlled material degradation
EP3960203A1 (de) 2020-08-25 2022-03-02 Université de Liège Komplexe zur abgabe von proteinischen wirkstoffen
US11956027B2 (en) 2020-08-28 2024-04-09 Isco International, Llc Method and system for mitigating interference by displacing antenna structures
US11476585B1 (en) 2022-03-31 2022-10-18 Isco International, Llc Polarization shifting devices and systems for interference mitigation
US11476574B1 (en) 2022-03-31 2022-10-18 Isco International, Llc Method and system for driving polarization shifting to mitigate interference
US11502404B1 (en) 2022-03-31 2022-11-15 Isco International, Llc Method and system for detecting interference and controlling polarization shifting to mitigate the interference
US11515652B1 (en) 2022-05-26 2022-11-29 Isco International, Llc Dual shifter devices and systems for polarization rotation to mitigate interference
US11509071B1 (en) 2022-05-26 2022-11-22 Isco International, Llc Multi-band polarization rotation for interference mitigation
US11509072B1 (en) 2022-05-26 2022-11-22 Isco International, Llc Radio frequency (RF) polarization rotation devices and systems for interference mitigation
US11990976B2 (en) 2022-10-17 2024-05-21 Isco International, Llc Method and system for polarization adaptation to reduce propagation loss for a multiple-input-multiple-output (MIMO) antenna
US11985692B2 (en) 2022-10-17 2024-05-14 Isco International, Llc Method and system for antenna integrated radio (AIR) downlink and uplink beam polarization adaptation
US11956058B1 (en) 2022-10-17 2024-04-09 Isco International, Llc Method and system for mobile device signal to interference plus noise ratio (SINR) improvement via polarization adjusting/optimization
US11949489B1 (en) 2022-10-17 2024-04-02 Isco International, Llc Method and system for improving multiple-input-multiple-output (MIMO) beam isolation via alternating polarization
CN116496492B (zh) * 2023-04-04 2024-09-06 兰州大学 植酸和多肽双重修饰的聚酰胺-胺型树枝状聚合物及其制备方法和应用
CN117959250A (zh) * 2024-03-27 2024-05-03 长春生物制品研究所有限责任公司 一种重组人白细胞介素-1受体拮抗剂注射液

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078302A1 (en) * 1999-06-19 2000-12-28 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same
WO2004060977A1 (en) * 2002-12-30 2004-07-22 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
IL83567A (en) 1986-08-18 1992-02-16 Dow Chemical Co Starburst conjugates with a carried material,such as an agricultural or pharmaceutical material
DE4310141A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidentale trifunktionelle Linker
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6585956B2 (en) * 1997-07-07 2003-07-01 The Dow Chemical Company Dendritic-platinate drug delivery system
AU1825299A (en) 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP2000306221A (ja) * 1999-04-22 2000-11-02 Nec Corp 磁気抵抗効果ヘッドおよびその製造方法
ITFO990015A1 (it) * 1999-07-23 2001-01-23 Verdini Antonio "dendrimeri polipeptidici quali trasportatori unimolecolari di farmaci e sostanze biologicamente attive".
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6410680B1 (en) * 2000-06-21 2002-06-25 Dendrimolecular, Inc. Dendrimer constructs and metal complexes thereof having superoxide dismutase activity
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
WO2002068454A2 (en) * 2001-02-21 2002-09-06 Batelle Memorial Institute Proteins in a porous support
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
CA2472917A1 (en) * 2002-01-08 2003-07-17 New River Pharmaceuticals Inc. Dendritic encapsulation of active agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078302A1 (en) * 1999-06-19 2000-12-28 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same
WO2004060977A1 (en) * 2002-12-30 2004-07-22 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005034909A2 *

Also Published As

Publication number Publication date
US20110172390A1 (en) 2011-07-14
EP3085388A1 (de) 2016-10-26
DK2090323T3 (en) 2016-11-07
CY1114972T1 (el) 2016-12-14
WO2005034909A3 (en) 2005-12-08
EP2090323B1 (de) 2016-07-27
HUE030243T2 (en) 2017-04-28
ES2451622T3 (es) 2014-03-28
US7879588B2 (en) 2011-02-01
EP1682186B1 (de) 2013-12-11
US8450097B2 (en) 2013-05-28
ES2600729T3 (es) 2017-02-10
EP2090323A1 (de) 2009-08-19
EP3085388B1 (de) 2021-04-07
CY1119457T1 (el) 2018-04-04
US20070020224A1 (en) 2007-01-25
SI2090323T1 (sl) 2016-11-30
EP1525890A1 (de) 2005-04-27
PL2090323T3 (pl) 2017-01-31
WO2005034909A2 (en) 2005-04-21
PT2090323T (pt) 2016-11-02
DK1682186T3 (en) 2014-03-03

Similar Documents

Publication Publication Date Title
EP1682186B1 (de) Hyperverzweigte polymer-Konjugate über nichtenzymatisch spaltbare Verbindungsglieder
Wu et al. Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges
EP1909845B1 (de) N,n-bis-(2-hydroxyethyl)glycin amid als verbindungsglied in polymer-konjugat-prodrugs
US9056126B2 (en) Hydrogel formulations
US9238686B2 (en) Polymeric prodrug with self-immolative linker
Sampathkumar et al. Dendrimers in cancer treatment and diagnosis
KR101592235B1 (ko) 단백질 케이지의 제조방법 및 소수성 첨가제를 담지한 코어-쉘 구조의 고분자-단백질 입자의 in-situ 제조방법
Dirks et al. Protein–polymer hybrid amphiphiles
EP1625856A1 (de) Hydrogel Polymer Prodroge Konjugate
Salmaso et al. Nanotechnologies in protein delivery
JP2006521372A (ja) 生物学的活性物質と生体適合性高分子の１：１接合体、この製造方法とこれを含む薬学組成物
JP2003506326A (ja) 診断イメージング造影剤、生物活性物質、および薬剤の単分子担体としてのポリペプチドデンドリマー
Tripathy et al. Dendrimer chemistry and host-guest interactions for drug targeting
Deng et al. Molecular Sieving with PEGylated Dendron-Protein Conjugates
EP2111872B1 (de) Hydrogel-konjugate
EP1625855A1 (de) Polymerische Prodrogen mit einer selbstimmolativen Verknüpfung
CN114790224B (zh) 一种微环境响应型树状多肽及其蛋白药物纳米载体与应用
Bhadra et al. PEGylated Dendritic Nanoparticulate Carriers of Anti-Cancer Drugs
KR20040086521A (ko) 생물학적 활성물질과 생체적합성 고분자의 1:1 접합체,이의 제조방법과 이를 함유하는 약학 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060428

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070322

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130605

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASCENDIS PHARMA GMBH

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 644122

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004043985

Country of ref document: DE

Effective date: 20140206

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20140224

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER AND PARTNER AG PATENT- UND MARKENANW, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2451622

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140328

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 644122

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140411

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004043985

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140912

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E021067

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004043985

Country of ref document: DE

Effective date: 20140912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140312

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131211

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602004043985

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0047480000

Ipc: A61K0047500000

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20171023

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20171019

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20170830

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181001

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181001

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230424

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231023

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231025

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231117

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231025

Year of fee payment: 20

Ref country code: IT

Payment date: 20231031

Year of fee payment: 20

Ref country code: IE

Payment date: 20231019

Year of fee payment: 20

Ref country code: HU

Payment date: 20231027

Year of fee payment: 20

Ref country code: FR

Payment date: 20231023

Year of fee payment: 20

Ref country code: DK

Payment date: 20231025

Year of fee payment: 20

Ref country code: DE

Payment date: 20231030

Year of fee payment: 20

Ref country code: CH

Payment date: 20231102

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004043985

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20240930

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20241001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240930

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240930

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20241025